Skip to content
2000
Volume 18, Issue 4
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

The complete eradication of Chronic Myeloid Leukemia is still challenging even in the era of highly selective and potent BCR-ABL tyrosine kinase inhibitors (TKIs). The ‘Achilles heel’ of TKI-based CML therapy is the inability of TKI to effectively target CML stem cells. Several pathways have been described to induce TKI insensitiveness in quiescent CML stem cells. In this review, we will describe the BCR-ABL/HAUSP/PML/PTEN network, whose signaling mediators converge to regulate the function of the tumor suppressor PTEN. We will also highlight the pharmacological strategies to modulate PTEN functions in order to sustain CML stem cell eradication.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450117666160608120527
2017-03-01
2025-06-24
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450117666160608120527
Loading

  • Article Type:
    Research Article
Keyword(s): BCR-ABL; chronic myeloid leukemia; HAUSP; PML; PTEN
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test